Tremfya — Sales to customers (Note 9)
Products & Services · Sales to customers (Note 9)Johnson & Johnson Tremfya — Sales to customers (Note 9) increased by 20.0% to $2.85B in Q3 2025 compared to the prior quarter. Year-over-year, this metric grew by 41.4%, from $2.01B to $2.85B. Over 2 years (FY 2021 to FY 2024), Tremfya — Sales to customers (Note 9) shows an upward trend with a 60.0% CAGR. This is a positive signal — higher values indicate stronger performance for this metric.
Analysis
How to read this metric
An increase indicates strong market penetration, successful commercial execution, or expanded clinical indications, while a decrease may signal increased competition, patent expiration, or loss of market share.
Detailed definition
This metric represents the total net revenue generated from the sale of a specific pharmaceutical product line within th...
Peer comparison
Comparable to specific drug or therapeutic class revenue reported by other large-cap pharmaceutical companies.
jnj_segment_tremfya_sales_to_customers_note_9Historical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q2 '23 | Q3 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $835.00M | $959.00M | $1.07B | $1.50B | $1.18B | $1.19B | $1.46B | $1.28B | $1.78B | $1.62B | $1.81B | $2.01B | $1.90B | $1.91B | $2.37B | $2.85B |
| QoQ Change | — | +14.9% | +12.0% | +40.0% | -21.5% | +1.1% | +22.3% | -12.3% | +39.3% | -9.4% | +12.1% | +11.1% | -5.8% | +0.7% | +24.2% | +20.0% |
| YoY Change | — | — | — | — | +41.3% | +24.4% | +35.8% | +8.5% | +49.5% | — | +41.6% | +13.0% | — | +18.3% | +31.0% | +41.4% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Johnson & Johnson's tremfya — sales to customers (note 9)?
- Johnson & Johnson (JNJ) reported tremfya — sales to customers (note 9) of $2.85B in Q3 2025.
- How has Johnson & Johnson's tremfya — sales to customers (note 9) changed year-over-year?
- Johnson & Johnson's tremfya — sales to customers (note 9) increased by 41.4% year-over-year, from $2.01B to $2.85B.
- What is the long-term trend for Johnson & Johnson's tremfya — sales to customers (note 9)?
- Over 2 years (2021 to 2024), Johnson & Johnson's tremfya — sales to customers (note 9) has grown at a 60.0% compound annual growth rate (CAGR), from $2.87B to $7.34B.
- What does tremfya — sales to customers (note 9) mean?
- The total net revenue earned from sales of a specific pharmaceutical product.